Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jan 25, 2024 12:37pm
101 Views
Post# 35845259

RE:RE:RE:RE:RE:CG Oncology

RE:RE:RE:RE:RE:CG Oncology
Note, I was not comparing products, all I did was say that cg oncology raised 437 million dollars end of story, I did not care whether it was introvenus administration or not and it would appear that the market did not care either or they would not have been able to raise that much money and they are already in a phase 3 so someone believes in them to allow for such a big IPO.
So what have we gotten so far for our 450 million dollars and over 23 years. Not even a phase 3 on the table at this time, only hope for that which we are all hoping for.
Nothing wrong with applauding another company that is doing well as you do it all the time pointing out all of the other companies that are being bought out at large valuations but are supposedly not as far along as we are.
We can go back and forth all day long but no matter what you or anyone thinks, the sp at this time says it all and no disputing that and also I would think that anyone all this board would say that sp does matter.
<< Previous
Bullboard Posts
Next >>